Companion Animal Arthritis Market Size by Animal Type, Type, Treatment, Distribution, Region – Segment-Level Market Assessment, Growth Opportunity Analysis, Competitive Mapping & Forecast to 2030
Overview
The Companion Animal Arthritis Market size was valued at USD 3.10 Billion in 2023 and the total Companion Animal Arthritis revenue is expected to grow at a CAGR of 7% from 2024 to 2030, reaching nearly USD 4.98 Billion.
Companion Animal Arthritis Market Overview
The companion animal arthritis market pertains to a condition that affects companion animals such as cats, dogs, and other exotic animals, causing inflammation in one or more joints due to cartilage wear and tear. Osteoarthritis, the most common type of arthritis in companion animals, frequently affects the hips, knees, and shoulders, and is more common in overweight or injured animals. Symptoms include reluctance to go on walks, difficulty getting up and down, crawling, and restlessness, as well as postural changes induced by spinal issues, thinning limbs from muscular atrophy, excessive licking, biting, or chewing, localized hair loss or inflammation, and low energy.
The companion animal arthritis market is expected to grow due to a rise in pet ownership and pet care expenditure worldwide, with the number of US homes with pets and pet care expenditures at an all-time high in 2023, as many pet owners view their pets as family members and invest more time and money in their care. However, the lack of good veterinary care in some countries may limit market growth opportunities. Industry growth is driven by several factors, including the growing companion animal population, the increase in the prevalence of arthritis, the rise in risk factors for the condition, government-supported awareness efforts, and the methods employed by major corporations.
To know about the Research Methodology :- Request Free Sample Report
Competitive Landscapes:
The Companion Animal Arthritis market is moderately competitive with a few key players dominating the majority of the market share. Due to the limited availability of products, both new entrants and established players are focused on launching new products to increase their market share. To maintain their market position, leading players are implementing various strategic initiatives such as competitive pricing strategies, partnerships, product and service expansion, sales and marketing initiatives, and mergers & acquisitions. For example, Zoetis received FDA approval in January 2022 for Solentia, a monoclonal antibody injection used to treat osteoarthritis pain in cats.
Key players are also enhancing their overall industry presence by launching new manufacturing units. In April 2022, Elanco collaborated with Ginkgo Bioworks to launch a new veterinary company BiomEdit to introduce engineered microbes and probiotics in veterinary care services. Such initiatives by companies and organizations are driving the growth of the Companion Animal Arthritis market. The market is not highly competitive, but the rivalry among key players is intense, leading to a constant need for innovation and strategic initiatives.
Companion Animal Arthritis Market Dynamics:
Increasing prevalence of obesity among the companion animals to Drive the Growth of Companion Animal Arthritis Market
The prevalence of obesity among companion animals is a significant factor driving the growth of the Companion Animal Arthritis market. Overfeeding and lack of physical activity in pets are the primary reasons for obesity, and pet owners often reward their pets with food, leading to overfeeding. Companion animals confined to houses or small yards without regular exercise are more likely to become overweight. In dogs, the risk of obesity is linked to the obesity of their owners, who may not walk their dogs enough. In cats, neutering increases the risk of obesity because of the lowered basal metabolic rate and reduced inclination to roam.
North America has a high prevalence of obesity in dogs, with 56% of dogs and 60% of cats classified as overweight or obese. The increasing prevalence of obesity in companion animals, including horses, is expected to drive the growth of the Companion Animal Arthritis market. Approximately 30% of the general canine population is obese, and 40-45% of dogs aged 5-11 years old weigh higher than normal. The market is expected to witness significant growth during the forecast period due to these factors.
Growing demand for Pet Healthcare Insurance to fuel the market growth
The rising demand for pet insurance due to growing animal health expenditure is expected to fuel the growth of the Companion Animal Arthritis market during the forecast period. Pet healthcare expenditure, which includes veterinary care, pet insurance policies, pet food, supplies/OTC medication, live animal purchases, and other services such as companion animal diagnostic and treatment services, has significantly increased in recent years. According to the American Pet Products Association (APPA), veterinary expenditure in the US has increased from USD 66.75 billion in 2016 to USD 109.6 billion by 2021.
Pet owners in the US spent USD 32.3 billion on vet care and product sales alone in 2021, up from USD 31.4 billion in 2020. This indicates that the number of pet owners investing in pet medical care has consistently risen yearly. The North American Pet Health Insurance Association (NAPHIA) reported that the pet insurance sector in North America exceeded USD 2.83 billion at the end of 2021, with industry growth more than doubling over the past four years (2018-2021). Pet insurance is gaining popularity as it helps pet owners manage the cost of preventive care, acute and chronic illnesses, and emergency medical care costs for their pets. This trend is expected to continue during the forecast period, fuelling the growth of the Companion Animal Arthritis market
Companion Animal Arthritis Market Segment Analysis:
Based on animal type, the market is segmented into dogs, cats and others. In 2023, the global market for pets was dominated by dogs with a share of over 60%, due to their high disease prevalence and rising adoption rates. The increasing dog population in every region is further fuelling market growth, with 45% of American households owning dogs in 2023and nearly 88 million European households owning pets. The COVID-19 pandemic has also driven people worldwide to adopt companion animals for psychological comfort.
The cats' segment is expected to expand at fastest CAGR due to the growing awareness among pet parents about the symptoms of arthritis in their cats. Almost 90% of cats suffer from arthritis, with larger breeds being more prone to osteoarthritis. However, timely diagnosis may be difficult due to cats' natural ability to hide pain, which could hinder early detection.
Based on Arthritis type, the market is segmented into Osteoarthritis, Rheumatoid Arthritis and others. In 2022, the Companion Animal Arthritis market was dominated by the osteoarthritis segment, which having a revenue share of over 75.0%. This was due to the high number of companion animals diagnosed with osteoarthritis. According to the American College of Veterinary Surgeons, around 25% of dogs in the United States are prone to developing osteoarthritis. Similarly, cats also suffer from this condition, which leads to clinical signs such as weight loss, depression, and limited mobility. The Veterinary Ireland Journal reported that nearly 40% of cats display these signs, and 90% of older cats develop osteoarthritis.
Rheumatoid arthritis segment is expected to grow significantly during the forecast period. Rheumatoid arthritis in dogs is a chronic condition that causes severe pain and inflammation in joints. Although it is less common than osteoarthritis, it still affects small cats and dogs significantly. Canine rheumatoid factor immunologic tests can diagnose rheumatoid arthritis in dogs in veterinary clinics or hospitals. Research studies have indicated that corticosteroids, cyclosporine, and NSAIDs are effective treatments for rheumatoid arthritis in companion animals.
By treatment, the market is categorised into Exercise, Medical and Others. The Companion Animal Arthritis market is dominated by the medication segment in 2023. This is due to the increasing prevalence of arthritis among pets caused by risk factors such as obesity, age, and nutritional impairments. Veterinary pharmaceutical companies are launching new products such as NSAIDs, opioids, steroids, stem cells, antibodies, and supplements to meet the rising demand for arthritis treatment among pet owners.
Supplements are initially prescribed by veterinarians for pets with less obvious symptoms of arthritis, which is also driving the demand for supplements among pet owners. In addition to medication, other treatments such as rehabilitation, lifestyle management, and novel medications are evolving to improve the quality of life for companion animals associated with arthritis. However, when medication fails to manage the arthritis condition in pets, surgical procedures such as joint replacement, joint fusion, and surgical removal of the affected joint are considered. Arthroscopy is a minimally invasive surgical approach that reduces postoperative pain in dogs and cats. Veterinarians also recommend non-medication treatment options such as weight management, environmental modifications, and physical rehabilitation to improve the health and well-being of pets with arthritis.
Based on Distribution Channel
The Companion Animal Arthritis market is comprised of various segments Veterinary Hospitals & Clinics, Retail Pharmacies, Online Stores and Others. The veterinary hospitals and clinics segment dominated the market in 2023. This is due to the increasing number of veterinary hospitals and clinics with advanced infrastructures that are crucial for pet healthcare. These clinics and hospitals help pet owners understand the proper dosage of arthritis medicine and ensure timely diagnosis, which is important for managing the condition. The growth of the veterinary hospitals and clinics segment is also attributed to the increasing number of veterinary professionals globally. For instance, in Europe, the number of veterinarians was approximately 263 million in 2019, according to the Federation of Veterinarians of Europe.
Other distribution channels such as retail pharmacies, online stores, and research institutes are also contributing to the growth of the Companion Animal Arthritis market. With more households owning companion animals, there is an increasing demand for convenient access to pet arthritis supplements and NSAIDs. Retail vet pharmacies offer various brands of oral supplements, NSAIDs, opioids, and essential oils for arthritis treatment in companion animals. Online sales of pet arthritic products have grown significantly during the COVID-19 pandemic as e-commerce platforms have become a convenient and easily accessible platform for purchasing pet medications.
The growing demand for arthritis treatment in companion animals has resulted in intense industry rivalry among pharmaceutical companies. As a result, companies are launching new products such as NSAIDs, opioids, steroids, stem cells, antibodies, and supplements to meet the rising demand for arthritis treatment among pet owners. Additionally, other treatments such as rehabilitation, lifestyle management, and novel medications are evolving to improve the quality of life for companion animals associated with arthritis. However, early detection and intervention play a crucial role in managing arthritis in pets, and pet owners should work closely with their veterinarians to ensure that their pets receive the appropriate treatment and care.
Companion Animal Arthritis Market Regional Insights:
By Region the market is segmented into North America, South America, Asia Pacific, Europe & Milled East Africa. According to a report, North America dominated the global Companion Animal Arthritis market in 2023 and is predicted to continue as the fastest-growing segment in the forecast period. The increase in pet adoption, especially dogs and cats, is contributing to the rise in demand for companion animal arthritis treatments in countries like the U.S. and Canada. The availability of treatments due to advancements in veterinary facilities is also driving the growth of this market in North America. In Europe, the presence of major players like Boehringer Ingelheim International GmbH contributed to the region holding the second-largest revenue share in 2023.
The Asia Pacific region is expected to have the highest CAGR during the forecast period, mainly due to rising animal healthcare expenditure and disposable income in key markets. The high adoption of companion animals, incidence of parasitic infections, and increasing awareness about the disease in developing countries like India are further boosting the growth of the market in this region. Additionally, a growing number of research activities, funding, and awareness campaigns in the field of veterinary health management are driving the growth of this market.
Companion Animal Arthritis Market Scope: Inquiry Before Buying
| Companion Animal Arthritis Market | |||
|---|---|---|---|
| Report Coverage | Details | ||
| Base Year: | 2023 | Forecast Period: | 2024-2030 |
| Historical Data: | 2018 to 2023 | Market Size in 2023: | USD 3.10 Billion |
| Forecast Period 2024 to 2030 CAGR: | 7% | Market Size in 2030: | USD 4.98 Billion |
| Segments Covered: | by Animal Type | 1.Dog 2.Cat 3.Others |
|
| by Type | 1.Osteoarthritis 2.Rheumatoid Arthritis 3.Others |
||
| by Treatment | 1.Medication 2.Exercise 3.Others |
||
| by Distribution | 1.Online Store 2.Pet Supply Store, 3.Veterinary Hospitals 4Clinics |
||
Companion Animal Arthritis Market by Region
North America (United States, Canada and Mexico)
Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe)
Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC)
Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A)
South America (Brazil, Argentina Rest of South America)
Companion Animal Arthritis Market Key Players:
1. Virbac,
2.Dechra Pharmaceuticals plc,
3.Vetoquinol Animal Health Pvt Ltd,
4. Phibro Animal Health Corp
5. Boehringer Ingelheim GmbH,
6.Bayer AG,
7. Ceva Sante Animale
8. Abbott Laboratories
9. Qiagen N.V.
10.Becton, Dickinson and Company
11. Quest Diagnostics, Inc.
12. Hologic, Inc.
13.F. Hoffmann-La Roche
14.Femasys, Inc.
15.Arbor Vita Corporation
16.NURX, Inc.
17.Seegene, Inc.
18.Thermo Fisher Scientific, Inc.
19. bioMérieux SA
FAQs:
1] What segments are covered in the Global Companion Animal Arthritis Market report?
Ans. The segments covered in the Companion Animal Arthritis report are based on animal type, arthritis type, treatment, distribution channel and region.
2] Which region is expected to hold the highest share in the Global Companion Animal Arthritis Market during the forecast period?
Ans. The North America region is expected to hold the highest share of the Companion Animal Arthritis market during the forecast period.
3] What is the market size of the Global Companion Animal Arthritis by 2030?
Ans. The market size of the Companion Animal Arthritis by 2030 is expected to reach USD 4.98 Bn.
4] What is the forecast period for the Global Companion Animal Arthritis Market?
Ans. The forecast period for the Companion Animal Arthritis market is 2024-2030.
5] What was the Global Companion Animal Arthritis Market size in 2023?
Ans. The Global Companion Animal Arthritis Market size was USD 3.10 Billion in 2023.